The American Journal of Managed Care4y
Comparing Factor Use and Bleed Rates in US Hemophilia A Patients Receiving Prophylaxis With 3 Different Long-Acting Recombinant Factor VIII Products
AFSTYLA ®, Antihemophilic Factor (Recombinant), Single Chain, is contraindicated in patients who have had life-threatening hypersensitivity reactions to AFSTYLA or its excipients, or to hamster ...